

November 17, 2010
FOR IMMEDIATE RELEASE

Ei Yamada, President and CEO

AnGes MG, Inc.

(Code No.4563, TSE Mothers)

Contact: Fumihiko Suzuki, Director, Corporate Planning Dept.

Tel: +81-3-5730-2480

**Regarding Evaluation and Supply Agreement toward Commercialization of DNA Vaccine
for Livestock against Swine Influenza
- GenomIdea, Inc., a Subsidiary of AnGes MG, Inc. Signs a Contract with Vical Inc. -**

GenomIdea, Inc. (hereafter called GenomIdea), a subsidiary of AnGes MG, Inc. has been pursuing the development of a highly efficient DNA vaccine for livestock against pandemic influenza as a project adopted for “The Okinawa New Industry Creation Research & Development Support Business”, supported by Okinawa Industry Promotion Public Corporation. AnGes MG is pleased to announce that GenomIdea and Vical Inc. (hereafter called Vical) entered into a contract for supply and evaluation of Vical’s H1N1 Influenza DNA vaccine in animals, including swine.

This contract indicates that in its efforts to develop a DNA vaccine, GenomIdea can utilize Vical’s influenza DNA vaccine (H1N1) and manufacture for evaluating its efficacy as a vaccine for livestock. GenomIdea will combine its unique technology with the DNA vaccine designed by Vical and evaluate its efficacy in animals of several kinds with the aim to commercialize it as a livestock vaccine.

It is presumed that in the future predicted pandemic of influenza, the virus is transmitted from livestock such as swine to human. Thus, preventing the outbreak of influenza among livestock is important. The DNA vaccine is a technology that allows vaccine to be manufactured within several weeks after a viral identification. By applying it to a technology with higher advantages that GenomIdea is currently considering, its practical application as a novel vaccine to prevent outbreak of influenza on the level of livestock is expected.

There will be only minimal effect of this agreement on the business performance during the current fiscal year. Thus, there will be no revision in the business forecast.